Publication: Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
No Thumbnail Available
Identifiers
Date
2022-08-11
Authors
Larkin, James
Weber, Jeffrey
Del Vecchio, Michele
Gogas, Helen
Arance, Ana M
Dalle, Stephane
Cowey, C Lance
Schenker, Michael
Grob, Jean-Jacques
Chiarion-Sileni, Vanna
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled patients per American Joint Committee on Cancer version 7 (AJCC-7) criteria. Here, we analyse long-term outcomes per AJCC-8 staging criteria compared with AJCC-7 results to inform clinical decisions for patients diagnosed per AJCC-8. In a double-blind, phase 3 trial (NCT02388906), patients aged ≥15 years with resected, histologically confirmed AJCC-7 stage IIIB, IIIC, or IV melanoma were randomised to receive nivolumab 3 mg/kg every 2 weeks or ipilimumab 10 mg/kg every 3 weeks for 4 doses and then every 12 weeks, both intravenously ≤1 year. Recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) were assessed in patients with stage III disease, per AJCC-7 and AJCC-8. Per AJCC-7 staging, 42.4% and 57.3% of patients were in substage IIIB and IIIC, respectively; per AJCC-8, 1.1%, 30.4%, 62.8%, and 5.0% were in IIIA, IIIB, IIIC, and IIID. After 4 years' minimum follow-up, the AJCC-7 superior efficacy of nivolumab over ipilimumab in patients with resected stage III melanoma was preserved per AJCC-8 analysis. No statistically significant difference in RFS between stage III substage hazard ratios was observed per AJCC-7 or -8 staging criteria (interaction test: AJCC-7, P = 0.8115; AJCC-8, P = 0.1051; P = 0.8392 ((AJCC-7) and P = 0.8678 (AJCC-8) for DMFS). CheckMate 238 4-year RFS and DMFS outcomes are consistent per AJCC-7 and AJCC-8 staging criteria. Outcome benefits can therefore be translated for patients diagnosed per AJCC-8.
Description
MeSH Terms
Adjuvants, Immunologic
Humans
Ipilimumab
Melanoma
Neoplasm Staging
Nivolumab
Skin Neoplasms
Humans
Ipilimumab
Melanoma
Neoplasm Staging
Nivolumab
Skin Neoplasms
DeCS Terms
CIE Terms
Keywords
AJCC-8 criteria, Distant metastases, Ipilimumab, Melanoma adjuvant therapy, Nivolumab, Recurrence-free survival, Stage 3